'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg

Novartis' experimental drug for amyotrophic lateral sclerosis (ALS) has failed in its latest clinical trial, marking another setback for the company's pipeline. This failure could impact Novartis' future revenue prospects and stock performance, as the market reacts to the news. The stock ticker for Novartis is NVS.